Please assess the completion status of the following clinical trial:

Trial Title: AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide written informed consent to participate in the study;~* Willing and able to comply with all study requirements and instructions of the site study staff;~* Must be ambulatory;~* Study knee must have a clinical diagnosis of osteoarthritis (OA) supported by radiological evidence (Kellgren Lawrence Grade IV) which is assessed locally (x-rays within the past 6 months of screening are acceptable);~* Moderate to moderately-severe OA pain in the study knee (rating of at least 1.5 on the WOMAC A, 5-point Likert Pain Subscale);~* Moderate to moderately-severe OA function in the study knee (rating of at least 1.5 on the WOMAC C, 5-point Likert Function Subscale);~* WOMAC A, 5-point Likert pain subscale \<1.5 in the contralateral knee;~* Ability to discontinue non-steroidal anti-inflammatory drug (NSAID) use at Screening visit and/or 72 hours prior to the Baseline visit and for the duration of the clinical study (low-dose aspirin (81 mg) is allowed during the study);~* No analgesia (including acetaminophen) taken 24 hours prior to an efficacy measure;~* No known clinically significant liver abnormality (e.g. cirrhosis, transplant, etc.).~Exclusion Criteria:~* As a result of medical review and screening investigation, the Principal Investigator considers the subject unfit for the study~* A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion)~* A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate)~* Presence of tense effusions~* Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint replacement in the affected knee, as assessed locally by the Principal Investigator~* Isolated patella femoral syndrome, also known as chondromalacia~* Any other disease or condition interfering with the free use and evaluation of the study knee for the duration of the trial (e.g. cancer, congenital defects, spine osteoarthritis)~* Major injury to the study knee within the 12 months prior to screening~* Severe hip osteoarthritis ipsilateral to the study knee~* Any pain that could interfere with the assessment of study knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee)~* Any pharmacological or non-pharmacological treatment targeting OA started or changed during the 4 weeks prior to randomization or likely to be changed during the duration of the study~* Pregnancy or planning to become pregnant during the study~* Use of the following medications:~  1. No intra-articular (IA) injected medications in the study knee during the study (or 12 weeks prior to Baseline).~ 2. No analgesics containing opioids.~ 3. NSAIDs are not permitted during the study; acetaminophen is available as a rescue medication during the study from the provided supply.~ 4. No topical treatment on the study knee during the study~ 5. No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study (treatment such as low-dose Aspirin (81 mg) and Plavix are allowed)~ 6. No systemic treatments that may interfere with safety or efficacy assessments during the study~ 7. No immunosuppressants~ 8. No use of systemic or intra-articular corticosteroids~* No human albumin treatment in the 3 months before randomization or throughout the duration of the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- AMPION™ 4 mL dose (Type: EXPERIMENTAL): 4 mL injection of Ampion
- Placebo 4 mL dose (Type: PLACEBO_COMPARATOR): 4 mL injection of Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).